Moreover, because ACE is identical with kinase II C the enzyme that degrades bradykinin, perindopril increases the bradykinins concentrations, mediating also their endogenous actions: nitric oxide (NO), prostaglandins, endothelial derived hyperpolarizing factor (EDHF) secretion, by stimulating B2 receptors of bradykinin. blockers, calcium channel blockers, and diuretics) in monotherapy, and 118 hypertensive patients under chronic treatment with perindopril. sEng?plasma levels were quantified and were correlated with classical methods of assessing the endothelial damage. Results: Patients under chronic treatment with perindopril experienced lower sEng plasma levels compared with the other group of hypertensive patients under different regimens of antihypertensive treatment (sEng: 4.731.39 versus 5.632.33, em Azomycin (2-Nitroimidazole) p /em 0.01). Conclusion: Decreased sEng plasma levels were found in patients Rabbit Polyclonal to RTCD1 under chronic treatment with perindopril, when compared with other antihypertensive regimens of treatment (beta blockers, calcium channel blockers, and/or diuretics). strong class=”kwd-title” Keywords: ACE inhibitors, essential arterial hypertension, endothelial dysfunction, antiangiogenic therapy, endoglin Introduction Endothelial dysfunction (ED), a characteristic of patients with essential arterial hypertension (either as a cause or as a consequence of hypertension), plays an important role in the development of atherosclerosis and plaque formation.1,2 It is characterized among others by increased vascular permeability, which facilitates the immune cells to enter in the sub-endothelial space, producing an inflammatory course of action which will later contribute to the accumulation of cholesterol molecules, the early stage of Azomycin (2-Nitroimidazole) atherogenesis.2,3 Open in a separate window Determine 4 Soluble endoglin plasma levels in Group B, in patients treated with calcium channel blockers. It was shown that soluble endoglin (sEng) plasma concentrations are increased in patients with atherosclerosis, hypertension or with diabetes mellitus and that sEng can be considered as a biomarker of endothelial damage.2 Endoglin (transforming growth factor- receptor III or CD 105) is a homodimeric transmembrane glycoprotein, which belongs to the family of zona pellucida of extracellular proteins. It is an accessory receptor for TGF- (transforming growth factor C ) superfamily and it regulates several cellular processes, such as: proliferation, differentiation, adhesion and migration.4 Two forms of CD105 are currently analyzed: a) a membrane form, expressed in various tissues and analyzed in some cardiovascular pathologies (atherosclerosis, preeclampsia, telangiectasia, hereditary hemorrhagia) and cancer and b) a soluble form (sEng), found in high concentrations in plasma after endothelial injury. sEng is usually expressed by the endothelial cells and has a crucial role in the functioning and homeostasis of the endothelium.5 Low concentrations of sEng were found in normal endothelial cells, being highly expressed in: inflamed endothelial cells,1 vascular injuries,6 tumor vessels,7 during embryogenesis,8 angiogenesis,9 vascular easy muscle cells of atherosclerotic plaque,10 fibroblasts, activated monocytes and macrophages.4 A hypertensive effect of high levels of sEng was shown in animal models and in patients with preeclampsia, sEng representing a possible disease severity biomarker, due to its interference with TGF-/TGF- pathway receptor and Azomycin (2-Nitroimidazole) thus inhibiting the eNOS (endothelial nitric oxide synthase) Cdependent vasodilatation.11,12 As well as other studies revealed that sEng increased the expression of P-selectin, E-selectin, soluble VCAM-1 and ICAM-1 on endothelium.11,12 Considering all the information presented above and also suggested by Rathouska J et al 2015, sEng might be an interesting biomarker to be studied in cardiovascular pathologies induced by ED or hypercholesterolemia under different regimens Azomycin (2-Nitroimidazole) of treatment, as a reflection of the efficacy of the treatment.2 Accordingly, this study aimed to quantify sEng plasma levels in hypertensive patients with endothelial dysfunction under different antihypertensive regimens of treatment. Material and methods A cross-sectional, comparative study was conducted from January 2015 to September 2016 in the Cardiology Medical center of Timisoara City Hospital, Romania. A total of 323 patients were enrolled in the present study, from which: 99 patients with normal values of blood pressure (Group A C control group), 106 hypertensive patients treated with different types of antihypertensive molecules (beta blockers: metoprolol 50 or 100 mg/day, carvedilol 12.5 or 25 mg/day, nebivolol 5 mg/day, bisoprolol 5 or 10 mg/day; calcium channel blockers: amlodipine 5 or 10 mg/day, lercanidipine 10 or 20 mg/day and diuretics: indapamide 1.5 or 2.5 mg/day, furosemide 20 mg+spironolactone 50 mg/day), in monotherapy (Group B) and 118 hypertensive patients treated with perindopril (5 or 10 mg/day), in monotherapy (Group C). All the patients were matched by age and sex. Individual selection All recruited patients completed the informed consent form and participated voluntary in the study. The patients enrolled in the control group were in the beginning examined for the suspicion of essential arterial hypertension, but the 24?hrs monitoring device did not confirm the diagnosis. The patients enrolled in.